Post-Covid Condition Cohort: Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors (SYNPOCov)
Post-Covid Condition Monitoring Cohort: Evaluation of the Evolution of Symptomatology, Patient Profile and Associated Prognostic Factors
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Francois GOEHRINGER, MD
- Phone Number: +33383154097
- Email: francois.goehringer@chru-nancy.fr
Study Locations
-
-
Grand Est
-
Vandoeuvre les nancy, Grand Est, France, 54511
- Recruiting
- Nancy University Hospital
-
Contact:
- Francois GOEHRINGER, MD
- Phone Number: +33383154097
- Email: francois.goehringer@chru-nancy.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- outpatients treated in the Nancy University Hospital Long Covid Support and Care Center for post-Covid condition according to WHO definition
Exclusion Criteria:
- patient opposing the processing for research purposes of their data collected in routine care for their care
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Symptoms
Time Frame: every 6 months up to 3 years
|
Symptoms collected in a standardized manner during consultations, their persistence over time, their evolution (improvement, stagnation, worsening) and their severity (mild, moderate, severe)
|
every 6 months up to 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medical history
Time Frame: baseline
|
baseline
|
|
|
fatigue
Time Frame: every 6 months up to 3 years
|
Chalder scale: range 0 to 33, >22/33 classified severe
|
every 6 months up to 3 years
|
|
Dyspnea
Time Frame: every 6 months up to 3 years
|
mMRC
|
every 6 months up to 3 years
|
|
Cognitive impairement
Time Frame: every 6 months up to 3 years
|
Montréal Cognitive Assessment : range 0 to 30, <26/30 classified pathologic
|
every 6 months up to 3 years
|
|
inappropriate hyperventilation syndrome
Time Frame: every 6 months up to 3 years
|
Nijmegen score: range 0 to 64, >23/34 classified "possible inapropriate hyperventilation" syndrome"
|
every 6 months up to 3 years
|
|
additional examinations
Time Frame: every 6 months up to 3 years
|
Biology, imaging
|
every 6 months up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Francois GOEHRINGER, MD, Infectious Diseases Department, Nancy University Hospital,F-54000 Nancy, France.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022PI148
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.